Company intelligence / Profile preview

GeneSys Biologics

Hyderabad, Telangana, Indiagenesysbiologics.com ↗

Ownership: Private
Employees: ~213
Development stage: Commercial

Overview

GeneSys Biologics has developed multiple insulin biosimilar candidates. Its lead product, Glargine, completed Phase I in India and was in Phase III as of late 2022; trials were expected to complete by February 2024 with commercial operations targeted for June 2024. The company has also completed preclinical toxicology studies for four products[4].

Therapeutic areas: Endocrinology
Modalities: Biosimilars (notably insulin biosimilars)
Industry: Biotech

Drug pipeline

3 assets

insulin human-gen1502

Unknown

2 more assets in the full pipeline.

Request access →

Partnerships

CIVICA Rx – co-development and commercialization agreement for three insulins (Glargine, Lispro, Aspart)[4].

Beyond the preview

Go deeper on GeneSys Biologics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GeneSys Biologics.

Explore the full profile